Pete, the problem with your idea is this -- if someone is in the end stages of cancer, it's useless to try to do a safety study because there's no way of telling whether they died because of the cancer, or because they had a bad reaction to the drug. Doing a study with people at death's door would taint the future prospects of the drug. It's unlikely that anyone at end stage would benefit even from a massive dose of Kevetrin.

I hope you've never been so unfortunate as to be with someone in the last few weeks of life, but if you had, you'd know that everything is such a struggle, and so uncertain at that point, that a study as you suggest would be futile. It could not help the drug's prospects, but it could hurt it.